WADA Prohibited is a recurring topic in our peptide coverage. This hub collects every article tagged WADA Prohibited, newest first, each evidence-graded and tied to real, verifiable sources.
A clinical, evidence-graded ranking of the peptides marketed for memory — Cerebrolysin, Semax, Noopept, Dihexa and P021 — separating the disputed human RCT signal from preclinical mechanism, a retracted-data scandal, and pure marketing.
An evidence-first review of the peptides men buy for muscle, testosterone, libido and recovery — graded honestly by human data, with the FDA and WADA status that marketing leaves out.
A clinical, evidence-graded review of the peptides marketed for sprains, MCL tears and ACL injury — where the rat data are genuinely ligament-specific, and why no human trial yet proves any of them heals a torn ligament.
An evidence-graded review of the peptides marketed for meniscus tears, ligament sprains, tendinopathy and cartilage wear. The honest 2026 verdict: no peptide has a placebo-controlled human knee trial — the strongest case is preclinical (rat surgery models) plus one uncontrolled human case series.
A clinical, evidence-graded review of the peptides marketed for joint health and joint pain — BPC-157, TB-500/thymosin β-4, GHK-Cu and ARA-290 — ranked honestly by the strength of their human vs preclinical data.
An evidence-graded review of the peptides marketed to 'injury-proof' tendons and ligaments. The honest 2026 verdict: prevention is the single most speculative claim in the peptide literature — no human prevention RCT, and no controlled animal prevention study, exists for any candidate.
An evidence-graded review of the peptides marketed for hip labral tears, femoroacetabular impingement, gluteal tendinopathy (GTPS) and hip bursitis. The honest 2026 verdict: no peptide has a human hip trial — the evidence tops out at animal models, while exercise and PRP hold the real human RCT data.
An evidence-first ranking of the GH secretagogues sold for 'growth hormone optimization' — tesamorelin, MK-677, CJC-1295, sermorelin and ipamorelin — separating what raises GH/IGF-1 in humans from what only sounds like it should.
A clinical, evidence-graded look at the peptides marketed for focus and "brain fog" — Semax, Selank, Cerebrolysin and the N-Acetyl modified analogs — separating the small human attention signal from preclinical mechanism and pure marketing.
A clinical, evidence-first review of the peptides marketed for fatigue and low energy — elamipretide (SS-31), thymosin alpha-1, MOTS-c, CJC-1295 and ipamorelin. The blunt headline: no peptide has a positive fatigue RCT in healthy people.
The honest fertility-peptide record: the strongest evidence belongs to the prescription reproductive hormones already in every IVF clinic — hCG, gonadotropins, gonadorelin — plus one investigational frontier, kisspeptin. No over-the-counter research peptide has human fertility data.
An evidence-graded review of the peptides marketed for endurance and aerobic performance — elamipretide (SS-31), MOTS-c and AOD-9604. The honest 2026 verdict: no peptide is proven to raise VO₂max or race performance in healthy humans, the category is preclinical-dominant, and MOTS-c is WADA-banned at all times.
Thymosin beta-4 (RGN-259) is the rare peptide with real, large human RCTs for the ocular surface — yet every pivotal Phase 3 missed its co-primary endpoint. A clinical-editorial ranking of what the dry-eye evidence actually supports in 2026.
A clinical, evidence-first look at the peptides pitched for lateral and medial epicondylitis — BPC-157 and TB-500/thymosin β-4 — and why both are graded C (preclinical only) for the elbow.
An evidence-graded ranking of the peptides marketed for cellulite — oral collagen peptides, GHK-Cu, AOD-9604 and HGH Fragment 176-191 — separating the one modest human signal from mechanism, marketing and WADA-banned research chemicals.
A clinical, evidence-graded look at the three peptides marketed for depression — Cerebrolysin, Selank and Semax — separating secondary-endpoint human data and preclinical antidepressant signals from marketing hype.
An evidence-graded review of the peptides marketed for cartilage and meniscus repair. The honest 2026 verdict: no peptide has a placebo-controlled human trial showing cartilage regrowth or meniscus repair, and the only controlled human data belongs to pentosan polysulfate — which is not even a peptide.
A clinical, evidence-graded review of the five peptides marketed for cardiovascular and heart health — elamipretide, angiotensin-(1-7), thymosin β4, TB-500 and BPC-157 — separating real human trials from preclinical and marketing claims.
LL-37, GHK-Cu, thymosin β4/TB-500 and BPC-157 all have real wound-healing biology — but not a single controlled human burn trial. A clinical-editorial ranking of what the evidence actually supports in 2026.
A clinical, evidence-ranked look at the peptides marketed for back injury, spinal soft-tissue repair, and disc health — what the published data actually supports, and what is marketing.
WADA Prohibited is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged WADA Prohibited, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.